Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Taylor

Otolaryngology Wyoming, MI Medical Doctor

NPI 1952427585 CMS profile 270385

1555 44Th St Sw, Wyoming, MI 49509

Open in the dashboard

General payments

$10,084

92 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Taylor of Wyoming, MI is reported in the CMS Open Payments database as having received $10,084 across 92 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $621 8
2024 General $1,049 8
2023 General $1,115 10
2022 General $1,318 14
2021 General $1,725 17
2020 General $966 11
2019 General $3,290 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Taylor
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Joseph Taylor were reported at $621. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Joseph Taylor Otolaryngology median Middle half National median
2019 $3,290 $194 $82–$512 $163
2020 $966 $118 $42–$280 $114
2021 $1,725 $167 $63–$444 $132
2022 $1,318 $216 $84–$545 $149
2023 $1,115 $235 $93–$588 $160
2024 $1,049 $280 $111–$699 $164
2025 $621 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intersect ENT, Inc. $5,320 38 payments
  2. Medtronic, Inc. $1,981 16 payments
  3. Stryker Corporation $1,234 10 payments
  4. Acclarent, Inc $935 17 payments
  5. Integra LifeSciences Corporation $224 3 payments
  6. Preceptis Medical, Inc. $149 2 payments
  7. Aerin Medical Inc. $143 1 payment
  8. Smith+Nephew, Inc. $64 3 payments
  9. Medtronic MiniMed, Inc. $19 1 payment
  10. Medtronic USA, Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,229 88 payments
  2. Travel and Lodging $1,854 4 payments
Products named General payments · program years 2019–2025
  1. PROPEL Otolaryngology (Ear, Nose, Throat) $4,814 34 payments
  2. SINUVA $2,137 7 payments
  3. NIM Vital $1,436 12 payments
  4. TruDi NAV Cable $701 10 payments
  5. SCOPIS ENT $539 3 payments
  6. PROPEL Otolaryngology (Ear, Nose, Throat) $419 3 payments
  7. ACCUGUIDE $267 2 payments
  8. CLARIFIX $239 2 payments
  9. ACCLARENT AERA $224 3 payments
  10. INSPIRA AIR $224 3 payments
  11. Other $1,954 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

300

Median for Otolaryngology: 297

Drug cost

$58,227

Median for Otolaryngology: $6,314

Branded share of claims

23.3%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 13 $46,993
Tobradex Tobramycin/Dexamethasone Brand 13 $3,366
Ipratropium Bromide Generic 74 $3,225
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 22 $2,364
Azelastine Hcl Generic 17 $494
Fluocinolone Acetonide Oil Generic 12 $420
Montelukast Sodium Generic 28 $336
Fluticasone Propionate Generic 30 $335
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 22 $320
Mupirocin Generic 25 $151

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$32,201

Medicare's payments for the services billed

Medicare patients

120

Average age 71

Services billed

746

65 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 43%
Ischemic heart disease 23%
Depression 21%
COPD 20%
Atrial fibrillation 18%
Chronic kidney disease 18%
Diabetes 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

92 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record